Report of transactions with shares and related securities of NeuroSearch by persons discharging managerial responsibilities and person/companies closely associated with these

Pursuant to section 28a of the Danish Act on Securities Trading, NeuroSearch
A/S (NEUR.CO) shall make public transactions with shares and related securities
of NeuroSearch A/S by persons discharging managerial responsibilities and
persons/companies closely associated with these. 

Name: Nicholas Waters
Reason: CEO of NeuroSearch Sweden AB
Issuer: NeuroSearch A/S 
ISIN code: DK0010224666
Transaction: Sale of shares
Trade date: 12 March 2010
Market: NASDAQ OMX Copenhagen A/S
Number (pcs): 5,000
Market value (DKK): 850,750

Name:Susanna Waters 
Reason: Related to Nicholas Waters, CEO of NeuroSearch Sweden AB
Issuer: NeuroSearch A/S 
ISIN code: DK0010224666
Transaction: Sale of shares
Trade date: 12 March 2010
Market: NASDAQ OMX Copenhagen A/S
Number (pcs): 5,000 
Market value (DKK): 850,750 



Contact person: 
Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, tel: +45 4460 8212 or +45 4017 5103 



About NeuroSearch - Company profile
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on NASDAQ
OMX Copenhagen A/S. The core business of the company covers the development of
novel pharmaceutical agents, based on a broad and well-established drug
discovery platform, focusing on ion channels and central nervous system (CNS)
disorders. A substantial share of the activities is partner financed through
strategic alliances with Janssen Pharmaceutica, Eli Lilly and Company and
GlaxoSmithKline, and licence collaboration with Abbott. The drug pipeline
comprises eight clinical (Phase I-III) development programmes: Huntexil®
(pridopidine) for Huntington's disease (Phase III), tesofensine for obesity
(ready for Phase III), ABT-894 for ADHD (Phase II) in partnership with Abbott,
ACR343 for schizophrenia (ready for Phase II), ACR325 to treat dyskinesias in
Parkinson's disease (Phase Ib), ABT-560 for the treatment of cognitive
dysfunctions (Phase I) in collaboration with Abbott, NSD-788 for
anxiety/depression (Phase I) and NSD-721 for social anxiety disorder (Phase I)
in partnership with GSK. In addition, NeuroSearch has a broad portfolio of
preclinical drug candidates and holds equity interests in several biotech
companies.